Abstract
Angiotensin converting enzyme (ACE) inhibitors have been shown to reduce the risk of death, worsening heart failure and recurrent infarction in patients with left ventricular dysfunction and heart failure. They have also been shown to reduce mortality in the acute phase of myocardial infarction. They have been demonstrated to reduce major vascular events and progression of renal disease in diabetes with hypertension, compared to placebo and to calcium channel blockers. Current trials are evaluating their role in preventing major vascular events in patients with coronary artery disease, strokes and Type II diabetes who are normotensive.
MeSH terms
-
Albuminuria / blood
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / mortality
-
Cardiovascular Diseases / prevention & control
-
Diabetes Mellitus, Type 1 / complications
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetic Retinopathy / prevention & control
-
Female
-
Humans
-
Hypertension / drug therapy
-
Kidney Diseases / prevention & control
-
Male
-
Meta-Analysis as Topic
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / prevention & control
-
Randomized Controlled Trials as Topic
-
Ventricular Dysfunction, Left / drug therapy
Substances
-
Angiotensin-Converting Enzyme Inhibitors